Market Place
Sourcing Support
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
08 Sep 2023 //
BUSINESSWIRE
Biocept Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
BUSINESSWIRE
Biocept Announces the Passing of Board Chair M. Faye Wilson
13 Jul 2023 //
BUSINESSWIRE
Biocept to Present at the Maxim Group Virtual Healthcare Conference
14 Jun 2023 //
BUSINESSWIRE
Poster Presented at ASCO Meeting Highlights Performance of Biocept’s CNSide
05 Jun 2023 //
BUSINESSWIRE
Biocept Reports Third Quarter 2022 Financial Results
21 Nov 2022 //
BUSINESSWIRE
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
18 Nov 2022 //
BUSINESSWIRE
Biocept to Participate in Study to Understand the Progression of Breast Cancer
16 Nov 2022 //
BUSINESSWIRE
Biocept Reports Second Quarter 2022 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide Assay
14 Oct 2022 //
BUSINESSWIRE
Plus Therapeutics, Biocept Announce Comprehensive Laboratory Services Agreement
22 Jun 2022 //
GLOBENEWSWIRE
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
16 May 2022 //
BUSINESSWIRE
Biocept Appoints Philippe Marchand as Chief Operating Officer
08 Mar 2022 //
BUSINESSWIRE
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
BUSINESSWIRE
Biocept Ppt at Molecular Medicine Meeting Highlights Potential of CNSide Assay
22 Feb 2022 //
BUSINESSWIRE
Biocept’s CNSide assay identifies tumor cells and biomarkers in metastatic NSCLC
21 Aug 2021 //
PHARMABIZ
Biocept Names David Karlander as Senior Vice President of Commercial Operations
04 Aug 2021 //
BUSINESSWIRE
Biocept to Participate in Two July Investment Conferences
19 Jul 2021 //
BUSINESSWIRE
Biocept inks lab services agreements with 2 IPAs for providing physicians
31 Dec 2020 //
PHARMABIZ
Biocept inks lab services agreements with 2 IPAs for providing physicians
30 Dec 2020 //
PHARMABIZ
Biocept`s assays viable and sensitive for detecting tumor cells and biomarkers
20 Nov 2020 //
SEEKING ALPHA
Biocept Announces Award of Japanese Patent, Platform to Detect Cell Mutations
23 Sep 2020 //
SEEKING ALPHA
Biocept receives Canadian patent entitled methods and reagents for signal
02 Jul 2020 //
PHARMABIZ
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced
02 Mar 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.